Fig. 1. SeCT therapy is a concept based on tagging specific cells in vivo with chemical moieties of therapeutic benefit.

The approach presented in this study is based on two key areas of research. The first is the development of tumor-targeting glycoalbumins. Proteins decorated with certain assemblies of complex N-glycans (i.e., α(2,3)sialic acid–terminated glycans) have been shown to exhibit preferential accumulation to certain tumor types in mice. The second is the development of gold-mediated, PE-based protein labeling. This reaction has allowed GArM complexes to be used for in vivo protein labeling.